Vadastuximab talirine

From WikiMD.org
Jump to navigation Jump to search

Vadastuximab talirine (pronunciation: vuh-dah-stuhk-see-mab tah-leer-een) is a monoclonal antibody-drug conjugate designed for the treatment of acute myeloid leukemia (AML) and other CD33-expressing hematologic malignancies.

Etymology

The name "Vadastuximab talirine" is derived from the components of the drug. "Vada" is a prefix used in pharmacology for monoclonal antibodies, "stux" refers to the target of the antibody, CD33, and "imab" indicates that it is a fully human antibody. "Talirine" refers to the cytotoxic agent that is conjugated to the antibody.

Mechanism of Action

Vadastuximab talirine binds to the CD33 antigen, which is expressed on the surface of myeloid leukemia cells. Upon binding, the drug is internalized and the cytotoxic agent is released, causing cell death.

Clinical Trials

Vadastuximab talirine has been evaluated in several clinical trials for the treatment of acute myeloid leukemia (AML) and other CD33-expressing hematologic malignancies. However, the development of the drug was discontinued in 2017 due to safety concerns.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski